Biofarma and Nutrilinea partner to form a European leader in the market of Health-care products
The size and organization of the newly formed group will allow it to become a point of reference in the global nutraceuticals sector
Milano, 20th December 2019 – Biofarma and Nutrilinea, leading players operating in the dietary supplements, medical devices and cosmetics products, announce a strategic partnership to create the leading European player in the research, development and production of Health-Care products.
Two entities that have continuously invested in human capital, quality, technology and innovation, will put together their respective distinctive assets and competences to support the growth of their clients in Italy and abroad.
The Group, with c. 170 million euro in revenues and above 600 employees, will have the size and organization to compete at global level, leveraging the values of quality, flexibility and service excellence that have always distinguished both companies.
The founders and main shareholders of Biofarma, Germano Scarpa and Gabriella Tavasani, will keep a relevant stake in the new Group which will maintain the Biofarma brand and will have its headquarters in Mereto di Tomba. They will continue to have a key role in the future development of the Group. Germano Scarpa will keep its position as Biofarma’s President and represent the company in the territory. Moreover, both founders will sit on the Board of Directors and be involved in research and development, management of large customers and communication and strategic development.
Maurizio Castorina, currently CEO of Nutrilinea, will become Group CEO while Giuseppe Giorgini, currently President of Nutrilinea, will keep its position and will continue to lead the acquisition strategy of the Group.
Marco Malaguti, currently GM of Biofarma, will become Group GM.
White Bridge Investments, Nutrilinea’s main shareholder, will maintain a majority stake in the Group.
Germano Scarpa and Gabriella Tavasani commented: “Biofarma has achieved remarkable results from an economic and an industrial standpoint. We believe that Nutrilinea represents the ideal partner to support Biofarma in its new growth phase in an increasingly competitive market environment. The combination of two leading companies, coming from different backgrounds but sharing common values, will allow us to invest in the future and the perpetuity of our company, ensuring a sustainable and long-lasting impact on our territory. Our key roles and direct involvement in the Group as shareholders and managers are a proof of our commitment and confidence in the growth potential of the Group that aims at reinforcing its leading position in the Health-Care products business.”
Maurizio Castorina, Nutrilinea’s CEO, added: “Biofarma is a long-standing and well-recognized player in the Health-Care products space, in particular nutraceuticals, medical devices and cosmetics. The Group will have access to a higher level of resources which are needed to achieve the objective of leadership in Europe. The Group will be a point of reference in the Italian health-care market, be able to attract new talents, invest in innovative projects, create new jobs and generate a sustainable and long-lasting impact on our territory.”
In the transaction Biofarma was assisted by Carlo Molaro, Tommaso Vidale and Marco Kraner from the firm Molaro-Pezzetta-Romanelli-Del Fabbro, acting as financial advisors, and by Luca Ponti, Francesca Spadetto and Paolo Panella from the Ponti & Partners law firm.
Nutrilinea was assisted by Matteo Delucchi and Beatrice Riva from the Giovannelli e Associati law firm, while Michele Aprile and Daniel Canola from the firm Ludovici & Partners worked on tax-related matters.
Biofarma and Nutrilinea were supported by Bain & Company in the definition of the integration plan and the operational due diligence, with a team led by partners Lorenzo Ferroni and Valerio Di Filippo, and managers Marzio Forlini, Matteo Luoni and Alessio Romitelli. Deloitte worked on the financial and tax due diligences, with a team led by Marco Bastasin on the financial aspects and Luca Bosco on the tax-related matters.